We publish no single base value for Mettler Toledo. Our valuation methods put it between $752.60 and $1,265.59 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
| Method | Value | vs price | Basis |
|---|---|---|---|
| Discounted cash flow | $752.60 | -56.5% | free cash flow $870.57m, growth 6.3% for 5 years, then fading to 3% over 5 more, discounted at 10.21%; stress floor $490.14 |
| Exit multiple (P/E) | $1,265.59 | -26.9% | earnings per share $47.82 valued at 33.71× (the stock's own median P/E) in 5 years, discounted back |
| Sum of the parts | — | — | no sum of the parts: this run holds no segment disclosure for the name |
| Price to sales | — | — | not reached: the cash-flow or earnings methods produced an anchor, so this fallback was not run |
| Tangible book | — | — | used only for lenders, where book value is the business |
| Price to FFO (REITs) | — | — | used only for REITs |
Each working is rebuilt by code from the valuation's own figures and checked against the published value.
The discount rate:
| Risk-free rate | 5.13% (10-year US Treasury yield) |
| Company's own beta | 1.17 (5 years of monthly returns against the S&P 500; standard error 0.19) |
| Peer beta | 1.20 (median of 8 S&P 500 Life Sciences Tools & Services companies) |
| Blend of own and peers | 1.19 (37% own, 63% peers, weighted by how precisely the company's own beta is measured) |
| Adjusted beta | 1.13 (0.67 × 1.19 + 0.33, pulled toward the market's 1.0) |
| Equity risk premium | 4.5% |
| Discount rate = risk-free + adjusted beta × premium | 10.21% |
Free cash flow grows 6.30% a year for 5 years, then fades in equal steps toward 3% over 5 more; each year is discounted by 1 ÷ (1 + rate)^year:
| Year | Growth | Free cash flow | Discount factor | Present value |
|---|---|---|---|---|
| Now | — | $870.57m | — | — |
| Year 1 | 6.30% | $925.41m | 0.9073 | $839.64m |
| Year 2 | 6.30% | $983.71m | 0.8232 | $809.82m |
| Year 3 | 6.30% | $1.05bn | 0.7469 | $781.05m |
| Year 4 | 6.30% | $1.11bn | 0.6777 | $753.31m |
| Year 5 | 6.30% | $1.18bn | 0.6149 | $726.55m |
| Year 6 | 5.75% | $1.25bn | 0.5579 | $697.12m |
| Year 7 | 5.20% | $1.31bn | 0.5062 | $665.40m |
| Year 8 | 4.65% | $1.38bn | 0.4593 | $631.80m |
| Year 9 | 4.10% | $1.43bn | 0.4167 | $596.74m |
| Year 10 | 3.55% | $1.48bn | 0.3781 | $560.66m |
| Terminal value = year-10 cash flow × (1 + 3%) ÷ (10.21% − 3%) | $21.17bn |
| Terminal value in today's money | $8.00bn |
| Present value of years 1–10 | $7.06bn |
| Total present value | $15.07bn |
| Shares outstanding | 20.02m |
| Value per share = total ÷ shares | $752.60 |
How the DCF value moves with the discount rate and the starting growth (the middle cell is the published value):
| Discount rate | Growth 1.3% | Growth 6.3% | Growth 11.3% |
|---|---|---|---|
| 9.21% | $650.60 | $878.28 | $1,181.34 |
| 10.21% | $562.05 | $752.60 | — |
| 11.21% | $494.99 | $657.70 | — |
The same DCF at each beta, starting growth unchanged:
| Beta | Value | Discount rate | DCF value |
|---|---|---|---|
| Company's own beta | 1.17 | 10.39% | $733.61 |
| Peer beta | 1.20 | 10.53% | $719.96 |
| Adjusted beta (used) | 1.13 | 10.21% | $752.60 |
Earnings per share grow on the same fading path as the DCF:
| Year | Growth | Earnings per share |
|---|---|---|
| Now | — | $47.82 |
| Year 1 | 6.30% | $50.83 |
| Year 2 | 5.47% | $53.61 |
| Year 3 | 4.86% | $56.21 |
| Year 4 | 4.39% | $58.68 |
| Year 5 | 4.04% | $61.06 |
| Earnings per share in year 5 | $61.06 |
| Exit P/E (the stock's own median P/E) | 33.71× |
| Value in 5 years = earnings × P/E | $2,058.24 |
| Discounted at 10.21% over 5 years: ÷ 1.6263 | $1,265.59 |
We publish no single base value for Mettler Toledo. Our valuation methods put it between $752.60 and $1,265.59 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
One-year price simulation: a 10% chance the price is below $1,335.83 and a 10% chance it is above $2,568.70 in a year; a 61% chance it is higher than today's $1,730.93, from 25.38% volatility. The simulation assumes the price drifts up at our discount rate of 10.21% a year.
At $1,730.93 the price implies free cash flow growing 20.9% a year for five years and then fading toward 3% over five more; its revenue has grown 6.3%.
| Week | Price | Base value |
|---|---|---|
| 2 Oct 2026 | $1,486.19 | — |
| 9 Oct 2026 | $1,549.99 | — |
| 16 Oct 2026 | $1,622.29 | — |
| 23 Oct 2026 | $1,670.29 | — |
| 30 Oct 2026 | $1,674.81 | — |
| 6 Nov 2026 | $1,722.15 | — |
| 12 Nov 2026 | $1,730.93 | — |
Data as of 12 Nov 2026; financials to 30 Sep 2026. Sources: company filings via EODHD, SEC EDGAR, US Treasury. How these values are computed. Not investment advice.
Run a full Desk Run on MTD · Mettler Toledo company page · Call and put prices